hIVIG
Showing 1 - 6 of 6
HIV Trial (Anti-HIV Immune Serum Globulin (Human), Zidovudine)
Terminated
- HIV Infections
- Anti-HIV Immune Serum Globulin (Human)
- Zidovudine
- (no location specified)
Oct 28, 2021
COVID, COVID-19, SARS-CoV-2 Trial in Worldwide (biological, other, drug)
Completed
- COVID
- +3 more
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
- +2 more
-
Colorado Springs, Colorado
- +38 more
Mar 31, 2022
COVID, SARS-CoV2 Infection, Covid19 Trial in Worldwide (Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo)
Recruiting
- COVID
- +2 more
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
- Placebo
-
Washington, District of Columbia
- +37 more
Mar 25, 2022
HIV Trial in Puerto Rico, United States (Anti-HIV Immune Serum Globulin (Human))
Completed
- HIV Infections
- Anti-HIV Immune Serum Globulin (Human)
-
Birmingham, Alabama
- +38 more
Oct 27, 2021
Influenza A, Influenza B Trial in Worldwide (Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG)
Completed
- Influenza A
- Influenza B
- Intravenous hyperimmune immunoglobulin (IVIG)
- Placebo for IVIG
-
San Diego, California
- +20 more
Nov 11, 2019
AIDS, Disease Transmission, Vertical, HIV Trial (immunoglobulins)
Completed
- Acquired Immunodeficiency Syndrome
- +2 more
- (no location specified)
Apr 13, 2016